Table 2 BCVA and other secondary outcomes.
Outcome | Levofloxacin (0.1 ml/0.5 mg) | Cefazolin (0.1 ml/1 mg) | Group difference* | |||
|---|---|---|---|---|---|---|
n | n | Ratio/mean (95% CI) | P value | |||
BCVA, median (IQR) | ||||||
Baseline | 25 | 0.32 (0.20, 0.48) | 25 | 0.28 (0.18, 0.48) | ||
Day 7 | 25 | 0.10 (0.02, 0.14) | 25 | 0.08 (0.02, 0.18) | 1.24 (0.65, 2.38) | 0.51 |
Month 1 | 25 | 0.02 (0.00, 0.04) | 25 | 0.02 (0.00, 0.04) | 1.28 (0.71, 2.34) | 0.40 |
Month 3 | 25 | 0.02 (0.00, 0.06) | 25 | 0.00 (0.00, 0.02) | 1.36 (0.75, 2.49) | 0.30 |
CFT, median (IQR) | ||||||
Baseline | 20 | 267 (246, 376) | 23 | 269 (252, 290) | ||
Month 1 | 25 | 267 (248, 283) | 25 | 271 (257, 294) | 0.99 (0.92, 1.07) | 0.82 |
Month 3 | 25 | 270 (258, 279) | 25 | 278 (261, 300) | 1.00 (0.91, 1.10) | 0.94 |
IOP, mean ± SD | ||||||
Baseline | 25 | 14.4 ± 2.6 | 25 | 13.7 ± 2.6 | ||
Day 7 | 25 | 13.5 ± 2.3 | 25 | 12.8 ± 3.0 | 0.5 (–1.0, 2.0) | 0.52 |
Month 1 | 25 | 13.1 ± 2.6 | 25 | 12.9 ± 2.6 | –0.1 (–1.4, 1.2) | 0.88 |
Month 3 | 25 | 12.6 ± 2.8 | 25 | 12.3 ± 2.4 | 0.1 (–1.4, 1.5) | 0.93 |
CCT, mean ± SD | ||||||
Baseline | 23 | 549 ± 31 | 25 | 564 ± 37 | ||
Month 1 | 23 | 578 ± 31 | 25 | 585 ± 44 | 8 (–10, 25) | 0.37 |
Month 3 | 24 | 563 ± 34 | 25 | 569 ± 43 | 7 (–10, 24) | 0.39 |
Cell density, mean ± SD | ||||||
Baseline | 25 | 2525 ± 441 | 25 | 2611 ± 428 | ||
Month 1 | 25 | 1779 ± 518 | 25 | 1907 ± 650 | –113 (–450, 223) | 0.50 |
Month 3 | 25 | 1838 ± 526 | 25 | 1984 ± 664 | –120 (–458, 217) | 0.48 |